The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer

The Potential of Congo Red Supplied Aggregates of Multitargeted Tyrosine Kinase Inhibitor (Sorafenib, BAY-43-9006) in Enhancing Therapeutic Impact on Bladder Cancer

Bladder cancer is a common malignancy associated with high recurrence rates and potential progression to invasive forms. Sorafenib, a multi-targeted tyrosine kinase inhibitor, has shown promise in anti-cancer therapy, but its cytotoxicity to normal cells and aggregation in solution limits its clinic...

Full description

Bibliographic Details
Main Authors: Małgorzata Lasota, Daniel Jankowski, Anna Wiśniewska, Michał Sarna, Marta Kaczor-Kamińska, Anna Misterka, Mateusz Szczepaniak, Joanna Dulińska-Litewka, Andrzej Górecki
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:International Journal of Molecular Sciences
Subjects:
bladder cancer
tyrosine kinases inhibitor
Congo red
personalized medicine
multidisciplinary treatment
Online Access:https://www.mdpi.com/1422-0067/25/1/269

Similar Items

Similar Items